Stockreport

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conferenc...

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged =2 yearsNew long-term data demonstr [Read more]